| Primary |
| Ventricular Tachycardia |
31.3% |
| Atrial Fibrillation |
12.0% |
| Ventricular Fibrillation |
8.3% |
| Cardiac Failure |
7.5% |
| Drug Use For Unknown Indication |
7.3% |
| Diabetes Mellitus |
5.1% |
| Hypertension |
3.0% |
| Infection |
3.0% |
| Angina Pectoris |
2.8% |
| Myocardial Infarction |
2.8% |
| Arrhythmia |
2.2% |
| Hypertrophic Cardiomyopathy |
2.0% |
| Cardiac Disorder |
1.8% |
| Atrial Flutter |
1.6% |
| Epilepsy |
1.6% |
| Parenteral Nutrition |
1.6% |
| Cardiac Failure Chronic |
1.4% |
| Hyperlipidaemia |
1.4% |
| Hyperuricaemia |
1.4% |
| Insomnia |
1.4% |
|
| Pneumonia |
12.1% |
| Interstitial Lung Disease |
10.6% |
| Renal Failure |
6.8% |
| Ventricular Tachycardia |
6.8% |
| Death |
6.1% |
| Pulmonary Alveolar Haemorrhage |
6.1% |
| Lung Disorder |
5.3% |
| Multi-organ Failure |
5.3% |
| Drug Ineffective |
4.5% |
| Hepatic Function Abnormal |
3.8% |
| Liver Disorder |
3.8% |
| Respiratory Failure |
3.8% |
| Thrombocytopenia |
3.8% |
| Ventricular Fibrillation |
3.8% |
| Condition Aggravated |
3.0% |
| Pneumonia Bacterial |
3.0% |
| Shock |
3.0% |
| Thyroiditis |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Hypernatraemia |
2.3% |
|
| Secondary |
| Ventricular Tachycardia |
21.3% |
| Cardiac Failure |
9.3% |
| Ventricular Fibrillation |
8.4% |
| Diabetes Mellitus |
7.6% |
| Drug Use For Unknown Indication |
7.6% |
| Atrial Fibrillation |
6.3% |
| Infection |
6.2% |
| Cardiomyopathy |
5.7% |
| Product Used For Unknown Indication |
4.1% |
| Angina Pectoris |
3.3% |
| Myocardial Infarction |
3.1% |
| Hypertension |
2.5% |
| Sedation |
2.5% |
| Cardiac Failure Chronic |
2.1% |
| Hyperlipidaemia |
2.0% |
| Parenteral Nutrition |
2.0% |
| Hypertrophic Cardiomyopathy |
1.7% |
| Angina Unstable |
1.5% |
| Atrial Flutter |
1.5% |
| Hypokalaemia |
1.5% |
|
| Ventricular Tachycardia |
16.5% |
| Pneumonia |
7.7% |
| Pneumonia Bacterial |
7.7% |
| Interstitial Lung Disease |
7.2% |
| White Blood Cell Count Increased |
6.2% |
| Hepatic Function Abnormal |
5.7% |
| Renal Failure |
5.7% |
| Death |
5.2% |
| Drug Ineffective |
4.6% |
| Thrombocytopenia |
4.6% |
| Pulmonary Alveolar Haemorrhage |
4.1% |
| Ventricular Fibrillation |
3.6% |
| Lung Disorder |
3.1% |
| Multi-organ Failure |
3.1% |
| Off Label Use |
3.1% |
| Agranulocytosis |
2.6% |
| Condition Aggravated |
2.6% |
| Renal Failure Acute |
2.6% |
| Cardio-respiratory Arrest |
2.1% |
| Hypoglycaemia |
2.1% |
|
| Concomitant |
| Cardiac Failure |
29.3% |
| Cardiac Failure Chronic |
12.5% |
| Product Used For Unknown Indication |
6.5% |
| Constipation |
5.7% |
| Atrial Fibrillation |
5.4% |
| Glaucoma |
5.0% |
| Prophylaxis |
4.7% |
| Diabetes Mellitus |
3.5% |
| Hyperuricaemia |
3.2% |
| Polyuria |
3.0% |
| Hypertension |
2.8% |
| Ventricular Tachycardia |
2.8% |
| Cerebral Artery Embolism |
2.7% |
| Hypothyroidism |
2.0% |
| Nausea |
2.0% |
| Ventricular Fibrillation |
2.0% |
| Insomnia |
1.8% |
| Pain |
1.8% |
| Dizziness |
1.7% |
| Ventricular Extrasystoles |
1.5% |
|
| Weight Increased |
11.0% |
| White Blood Cell Count Decreased |
11.0% |
| Anaphylactic Shock |
6.8% |
| Multi-organ Failure |
6.8% |
| Renal Impairment |
6.8% |
| White Blood Cell Count Increased |
6.8% |
| Cardiac Failure |
5.5% |
| Ventricular Tachycardia |
5.5% |
| Hyperkalaemia |
4.1% |
| Platelet Count Decreased |
4.1% |
| Thirst |
4.1% |
| Urinary Tract Infection |
4.1% |
| Vomiting |
4.1% |
| Asthenia |
2.7% |
| Cardiac Failure Congestive |
2.7% |
| Death |
2.7% |
| Drug Ineffective |
2.7% |
| Hepatic Function Abnormal |
2.7% |
| Hyperbilirubinaemia |
2.7% |
| Hypernatraemia |
2.7% |
|
| Interacting |
| Atrial Fibrillation |
42.2% |
| Atrial Flutter |
23.5% |
| Restless Legs Syndrome |
15.7% |
| Hyperparathyroidism Secondary |
7.8% |
| Hypothyroidism |
7.8% |
| Cardiac Failure |
2.0% |
| Renal Cell Carcinoma Stage Iv |
1.0% |
|
| Hyperkalaemia |
80.0% |
| Prothrombin Time Prolonged |
10.0% |
| Ventricular Tachycardia |
10.0% |
|
